Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL685134 | 0.87 | SLC6A4 (0.70) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL684950 | 0.87 | SLC6A9 (0.62) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL13042191 | 0.85 | SLC6A9 (0.54) | SLC6A9SLC6A4HRH3ALDH1A1CYP2D6 | |
| SCHEMBL684106 | 0.84 | SLC6A9 (0.56) | SLC6A9SLC6A4HRH3ALDH1A1CYP2D6 | |
| SCHEMBL10076387 | 0.84 | SLC6A4 (0.79) | SLC6A9SLC6A4HRH3ALDH1A1CYP2D6 | |
| SCHEMBL685396 | 0.82 | SLC6A9 (0.57) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL5533459 | 0.82 | SLC7A5 (0.55) | SLC6A9SLC6A4HRH3CYP2D6CYP2C9 | |
| SCHEMBL1582713 | 0.81 | SLC6A9 (0.58) | SLC6A9SLC6A4HRH3MAPT | |
| SCHEMBL6565529 | 0.81 | SLC6A9 (0.83) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| Oxalic Acid SCHEMBL5142654 | 0.81 | SLC6A9 (0.68) | SLC6A9SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2017-01-12 | — | — | US | disclosed |
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2015-05-21 | — | — | US | disclosed |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A9 4130/4885SLC6A4 978/4885HRH3 555/4885 |
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A9 4130/4885SLC6A4 978/4885HRH3 555/4885 |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A9 4130/4885SLC6A4 978/4885HRH3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.